Evidence map›Paper›PMID 41310891›Full record

ReviewJournal of medical case reports2025

Congenital hepatic arteriovenous fistula: a case report and review of the literature.

Xinghui Yu, Abdisamat Ababakri, Yan Xie, Wentao Jiang

Abstract readCase ReportsReview
In one paragraph

Review in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xinghui YuSchool of Medicine, Nankai University, Tianjin, China.
Abdisamat AbabakriFirst Central Clinical School, Tianjin Medical University, Tianjin, China.
Yan XieTianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Tianjin First Center Hospital, Tianjin, 300192, China.
Wentao JiangSchool of Medicine, Nankai University, Tianjin, China. jwt001@163.com.

Funding

the Independent Research Fund of the Institute of Transplant Medicine at Nankai University NKTM2023004the Key Discipline Special Project of Tianjin Municipal Health Commission TJWJ2022XK016the Key Project of Tianjin Science and Technology Bureau Applied Basic Research 23JCZDJC01200
6 · The paper itself

Abstract

backgroundHepatic arteriovenous fistula refers to the direct abnormal communication between the hepatic artery and the portal vein or hepatic vein. Clinical symptoms of hepatic arteriovenous fistula primarily depend on the blood flow volume, location, and duration of the fistula. Symptoms may include liver fibrosis, portal hypertension, enlarged heart, and ultimately heart failure. Congenital hepatic artery-portal fistula is a rare condition, predominantly observed in children or infants. Although interventional hepatic artery embolization is typically the initial treatment choice, it may not always be effective. CASE PRESENTATION: We present a case of a 22-year-old Chinese male patient with hepatic arteriovenous fistula who underwent multiple interventional therapies. The patient was diagnosed with "hepatic artery-portal fistula, viral hepatitis B, and ascites" at Shengjing Hospital in August 2018, following complaints of abdominal distension. Hepatic artery embolization and diuretic treatment were administered, resulting in symptom relief. However, after discharge, the patient experienced recurrent abdominal distension, hematemesis, and melena. Consequently, hepatic artery embolization was performed periodically in May 2020, November 2020, January 2021, May 2021, and August 2021 to manage these conditions. During the hepatic artery embolization procedure, the contrast agent was monitored entering the portal vein directly from the hepatic artery. In the present case, interventional therapy was unable to completely block the fistula, providing only temporary relief. Consequently, liver transplantation is considered the ultimate treatment option for complex and diffuse intrahepatic vascular fistulas following hepatic artery embolization. The patient has currently been approved and registered for liver transplantation.

conclusionsPatients with diffuse hepatic arteriovenous fistula are prone to symptoms of portal hypertension, such as gastrointestinal bleeding caused by esophageal-gastric varices and ascites resulting from poor venous return, which significantly impact patient safety and quality of life. Arterial embolization provides only temporary symptom control. In cases where diffuse hepatic arteriovenous fistula is suspected or when interventional treatment fails, prompt liver transplantation should be considered. Therefore, this case report aims to enhance the understanding of the timing and selection of hepatic arteriovenous fistula treatment, along with providing a review of previous studies.

Indexed as

Arteriovenous FistulaEmbolization, TherapeuticHepatic ArteryHepatic VeinsPortal VeinHumansMaleYoung AdultCongenital hepatic arteriovenous fistulaHepatic artery embolizationLiver transplantationPortal hypertension

Identifiers

PMID41310891
PMCPMC12763836

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.